DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction

Biochemical Pharmacology

Volumn 52, Issue 11, 1996, Pages 1729-1734

  Köberle, Beate ^a,b   Payne, Joachim ^a   Grimaldi, Keith A ^b   Hartley, John A ^b   Masters, John R W ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c 3rd Floor Research Laboratories ^*  (United Kingdom)

Author keywords

cisplatin; DNA repair; drug response; quantitative PCR; testis tumours

Indexed keywords

CISPLATIN; DNA; PLATINUM;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG UPTAKE; GENE; GENETIC TRANSCRIPTION; GERM CELL TUMOR; HUMAN; HUMAN CELL; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA REPAIR; DRUG RESISTANCE; HUMANS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0030582839     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00549-7     Document Type: Article

References (25)

1. 1. Loehrer PJ and Einhorn LH, Cisplatin. Ann Intern Med 100: 704-713, 1984.
2. 2. deGraeff A, Slebos RJC and Rodenhuis S, Resistance to cisplatin and analogues: Mechanisms and potential clinical implications. Cancer Chemother Pharmacol 22: 325-332, 1988.
3. 3. Andrews PA and Howell SB, Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cell 2: 35-43, 1990.
4. 4. Gately DP and Howell SB, Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67: 1171-1176, 1993.
5. 5. Oldenburg J, Begg AC, van Vugt MJH, Ruevenkamp M, Schornagel JH, Pinedo HM and Los G, Characterization of resistance mechanism to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res 54: 487-493, 1994.
6. 6. Johnson SW, Ferez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC, Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689-697, 1994.
7. 7. Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF and Hamilton TC, Relationship between platinum DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin sensitive and resistant human ovarian cancer cells. Cancer Res 54: 5911-5916, 1994.
8. 8. Zhen W, Link CJ, O'Connor PM, Reed E, Parker R, Howell S and Bohr VA, Increased gene specific repair of cisplatin interstrand crosslinks in cisplatin resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698, 1992.
9. 9. Pera MF, Friedlos F, Mills J and Roberts JJ, Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res 47: 6810-6813, 1987.
10. 10. Bedford P, Fichtinger-Schepman AMJ, Shellard SA, Walker MC, Masters JRW and Hill BT, Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48: 3019-3024, 1988.
11. 11. Melvik JE, Dornish JM, Tonini GP and Pettersen EO, Characterisation of a human cell line of cervix carcinoma origin, NHIK 3025/DDP, resistant to cis-diamminedichloroplatinum(II). Cell Pharmacol 1: 9-16, 1993.
12. 12. Timmer-Bosscha H, Timmer A, Meijer C, de Vries EGE, de Jong B, Oosterhuis JW and Mulder NH, Cis-diamminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cell lines. Cancer Res 53: 5705-5713, 1993.
13. 13. Walker MC, Povey S, Parrington JM, Knuchel R, Riddle PN and Masters JRW, Development and characterization of cis-platin-resistant human testicular and bladder tumour cell lines. Eur J Cancer 26: 742-747, 1990.
14. 14. Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ and Harrap KR, Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52: 1710-1716, 1992.
15. 15. Grimaldi KA, Bingham JP, Souhami RL and Hartley JA, DNA damage by anticancer agents: Mapping in cells at the subgene level with quantitative PCR. Anal Biochem 222: 236-242, 1994.
16. 16. Kuppen PJK, Schuitenmaker H, Van'tVeer LJ, de Bruijin EA, van Oosterom AT and Sender PI, Cis-diamminedichloroplatinumf (II)-resistant sublines derived from two human ovarian carcinoma cell lines. Cancer Res 48: 3355-3359, 1988.
17. 17. Ishikawa T, Wright CD and Ishizuka H, GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269: 29085-29093, 1994.
18. 18. Fujii R, Mutoh M, Sumizawa T, Chen ZS, Yoshimura A and Akiyama S. Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J Natl Cancer Inst 86: 1781-1784, 1994.
19. 19. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AMJ and Shellard SA, Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30A: 832-837, 1994.
20. 20. Eastman A, Separation and characterization of products resulting from the reaction of cis-diammine-dichloroplatinum (II) with deoxyribonucleosides. Biochemistry 21: 6732-6736, 1982.
21. 21. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL and Chaney SG, Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54: 3500-3505, 1994.
22. 22. Pillaire MJ, Margot A, Villani G, Sarasin A, Defais M and Gentil A, Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acid Res 22: 2519-2524, 1994.
23. 23. Hoffmann J-S, Pillaire M-J, Maga G, Podust V, Hubscher U and Villani G, DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA 92: 5356-5360, 1995.
24. 24. Richards EH, Hickey E, Weber L and Masters JRW, Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56: 2446-2451, 1996.
25. 25. Chresta CM, Masters JRW and Hickman JA, Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56: 1834-1841, 1996.